Nivolumab-induced endocrinopathy

Abstract

Inhibitors of immune control points (ICP) is a new group of drugs used to treat patients with incurable neoplasias, in particular their metastatic forms. However, there is a risk of developing immune-mediated adverse events from a number of organ systems during therapy with these drugs. Immune-mediated adverse events are understood as a side effect due to excessive activation of the immune system with autoimmune damage to normal tissues of various organs and systems, and not the main goal of immunotherapy. In particular, one of these side effects when using ICP is the development of endocrinopathies (thyroiditis, hypophysitis, adrenalitis, type 1 diabetes mellitus). We present a literature review and a clinical case of the development of hypothyroidism, hyponatremia and psychosis in a patient after nivolumab therapy for recurrent colorectal cancer 3 months after immunotherapy.